These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 11489818)

  • 1. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
    Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
    Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
    Konecny G; Untch M; Pihan A; Kimmig R; Gropp M; Stieber P; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Jun; 7(6):1743-9. PubMed ID: 11410515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
    Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
    Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
    Nishikawa A; Iwasaki M; Akutagawa N; Manase K; Yamashita S; Endo T; Kudo R
    Gynecol Oncol; 2000 Nov; 79(2):256-63. PubMed ID: 11063654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.
    Schmalfeldt B; Kuhn W; Reuning U; Pache L; Dettmar P; Schmitt M; Jänicke F; Höfler H; Graeff H
    Cancer Res; 1995 Sep; 55(18):3958-63. PubMed ID: 7664262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.
    Kuhn W; Pache L; Schmalfeldt B; Dettmar P; Schmitt M; Jänicke F; Graeff H
    Gynecol Oncol; 1994 Dec; 55(3 Pt 1):401-9. PubMed ID: 7835780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
    Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
    BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
    Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
    Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
    Kuhn W; Schmalfeldt B; Reuning U; Pache L; Berger U; Ulm K; Harbeck N; Späthe K; Dettmar P; Höfler H; Jänicke F; Schmitt M; Graeff H
    Br J Cancer; 1999 Apr; 79(11-12):1746-51. PubMed ID: 10206287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain-derived neurotrophic factor inducing angiogenesis through modulation of matrix-degrading proteases.
    Sun CY; Hu Y; Wang HF; He WJ; Wang YD; Wu T
    Chin Med J (Engl); 2006 Apr; 119(7):589-95. PubMed ID: 16620701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
    Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
    Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
    Knappe UJ; Hagel C; Lisboa BW; Wilczak W; Lüdecke DK; Saeger W
    Acta Neuropathol; 2003 Nov; 106(5):471-8. PubMed ID: 12904990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
    Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
    Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
    Zhang W; Ling D; Tan J; Zhang J; Li L
    Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells.
    Rosanò L; Varmi M; Salani D; Di Castro V; Spinella F; Natali PG; Bagnato A
    Cancer Res; 2001 Nov; 61(22):8340-6. PubMed ID: 11719468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
    Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A
    Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.
    Dorn J; Harbeck N; Kates R; Magdolen V; Grass L; Soosaipillai A; Schmalfeldt B; Diamandis EP; Schmitt M
    Biol Chem; 2006 Aug; 387(8):1121-8. PubMed ID: 16895483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles.
    Graves LE; Ariztia EV; Navari JR; Matzel HJ; Stack MS; Fishman DA
    Cancer Res; 2004 Oct; 64(19):7045-9. PubMed ID: 15466198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of KiSS-1, matrix metalloproteinase-9, nuclear factor-kappaBp65 in ovarian tumour].
    Gao GL; Liu LD; Zou XS; Chen WX
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):34-8. PubMed ID: 17331419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.